Sarepta Therapeutics Inc
NASDAQ: SRPT
$127.85
+$2.84 (+2.3%)
Real Time Data Delayed 15 Min.
SRPT Articles
The top analyst upgrades, downgrades and initiations for Friday included Adobe, Biogen, Bristol-Myers, Broadcom, Charles Schwab, Ciena, Etsy, Gilead, Oracle, Sarepta, Snap and Wayfair.
Published:
Last Updated:
Friday's top analyst upgrades, downgrades and initiations included Arista Networks, Booking, Dunkin' Brands, DuPont, GameStop, Generac, PBF Energy, Pinterest, Square and YETI.
Published:
Sarepta shares jumped on Friday after the firm announced an update from its Duchenne muscular dystrophy trial.
Published:
One sector that has avoided much of the current trade and recession fear turmoil is health care, and especially the biotech companies. The four top stocks have gigantic implied upside.
Published:
Last Updated:
Tuesday was a breakout day for a few biotech companies that saw either huge gains or massive losses. 24/7 Wall St. has picked a few of those standouts to highlight.
Published:
Last Updated:
The included AbbVie, Beyond Meat, Bio-Rad Laboratories, Dell Technologies, HP, Jumia Technologies, Nabriva Therapeutics, PG&E, Salesforce.com and Sarepta Therapeutics.
Published:
Last Updated:
With the market clearly close to, or at full value, it makes sense to look to areas where alpha can be generated for the rest of 2019. These five top stocks are the best picks from the Merrill team...
Published:
Last Updated:
With the three major stock indexes trading at or near all-time highs, many investors are scratching their heads about where to look for new investment ideas at a time when interest rates have become...
Published:
Last Updated:
Pfizer released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy. While these results did not necessarily live up to expectations, there is a winner in this.
Published:
Last Updated:
These are the top analyst upgrades and downgrades for Friday, June 21, 2019. There are many stocks to Buy, including NLY, FISV, KEY, PSX and others.
Published:
Last Updated:
Spark Therapeutics shares more than doubled in Tuesday’s session as the result of its pending acquisition. However, the root of the buyout was its gene therapy, which could drive more acquisitions...
Published:
Last Updated:
Many Wall Street firms are issuing their top picks and listing their favorite sectors and trends to consider for the year ahead. Credit Suisse is one of those firms.
Published:
Last Updated:
After a big stock market sell-off and a subsequent snap-back rally, it’s always interesting to see how corporate directors are acting toward their own shares. It’s no secret that corporate...
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Thursday include Chevron, First Data, JD.com, MongoDB, PG&E, Rite Aid, Tilray and Vodafone.
Published:
Last Updated:
La Jolla Pharmaceutical and Sarepta Therapeutics are among seven biotech stocks that have seen some notable insider trading recently.
Published:
Last Updated: